Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Novartis AG — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.4 (market cap $2.16B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 138× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| AMC | NVS | |
|---|---|---|
Market Cap | $2.16B | $298.18B |
Sector | Media | Health |
52-Week High | $3.15 | $168.62 |
52-Week Low | $0.95 | $119.31 |
Enterprise Value | $9.10B | $339.50B |
Dividend Yield | 0.11% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.59, up 0.78% today, with a bullish technical signal and recent earnings beats. The stock is testing the $3.00 resistance level, supported by record box office performance and improved cash flow trends. However, the company remains unprofitable with a net income margin of -10.59% and high debt levels, though valuation ratios like P/S of 0.28 and P/B of 0.64 suggest potential undervaluation.
Outlook is cautiously optimistic due to strong revenue growth and cost discipline, but risks include persistent losses and heavy debt burden. Analyst consensus price target is $3.00, with 32% buy ratings, indicating moderate upside potential if operational improvements continue.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
